Inbios International Inc.
Seattle, WA
- UEI
- CNJNQ1GMSN55
- CAGE
- 3KJL6
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 307 Westlake Ave N #300, Seattle, WA 98109, USA
- Website
- inbios.com
- Founded
- 1996
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Inbios reagents kits | CDC Pittsburgh | $62,258 | |
| Topic 455: development of a rapid at-home test to detect prostate-specific antigen using self-collected finger… | National Cancer Institute | $399,866 | |
| 8510704349 ! Test kit,visceral l | Medical Supply Chain | $4,708 | |
| 8510632304 ! Test kit,visceral l | Medical Supply Chain | $856 | |
| Development of next-GEN chagas detecttm plus rapid test for sensitive and specific diagnosis of chagas disease -… | National Institute of Allergy and Infectious Diseases | $3,963,327 |
About Inbios International Inc.
Inbios International Inc. is a minority-owned, for-profit biotechnology company based in Seattle, Washington, specializing in the design, development, and manufacture of immunodiagnostic devices for infectious diseases. The company is registered in SAM.gov and operates as a Subchapter S Corporation, with a focus on creating innovative diagnostic solutions for various health challenges. Inbios provides a range of products and services to federal agencies, including rapid diagnostic tests, research and development of medical technologies, and production of test kits for infectious diseases.
Through federal contract awards, Inbios has been a critical partner to multiple government agencies, particularly during the COVID-19 pandemic. The company has secured numerous contracts with agencies like the Department of Health and Human Services, the Defense Logistics Agency, the Department of Defense, and the Centers for Disease Control and Prevention. These contracts have included procuring over-the-counter COVID-19 tests, developing diagnostic devices, expanding production capacity, and supplying various test kits for visceral and cutaneous applications. The contract awards have ranged from small purchase orders of a few thousand dollars to substantial contracts valued at over $52 million, with many contracts supporting pandemic response efforts. Most of these contracts were awarded through open competition, with a few set aside for small businesses, particularly under the Small Business Innovation Research (SBIR) program.
Inbios has also received federal grant awards focused on developing advanced diagnostic technologies for infectious diseases. The National Institute of Allergy and Infectious Diseases (NIAID) has been a primary funding agency for these grants. Notable grant projects include developing a next-generation "Chagas Detect Plus" rapid test for diagnosing Chagas disease, with a goal of creating a test with 97% sensitivity and 95% specificity. Another grant project focused on developing a point-of-care antigen detection assay for early diagnosis of Ebola Virus Disease. These grants demonstrate Inbios's commitment to advancing diagnostic capabilities for neglected tropical diseases and emerging infectious diseases. The grants typically support research and development phases, with the ultimate aim of creating FDA-clearable diagnostic technologies that can be deployed in various healthcare settings.
SBA capabilities narrative
InBios develops and manufactures in-vitro diagnostic tests for human and veterinary use. The company also performs assay development and contract manufacturing
Quick answers
What is Inbios International Inc.'s UEI?
Inbios International Inc.'s Unique Entity ID (UEI) in SAM.gov is CNJNQ1GMSN55.
What is Inbios International Inc.'s CAGE code?
Inbios International Inc.'s CAGE code is 3KJL6.
What is Inbios International Inc.'s primary NAICS code?
Inbios International Inc.'s primary NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing).
Where is Inbios International Inc. located?
Inbios International Inc.'s physical address in SAM.gov is 307 Westlake Ave N #300, Seattle, WA 98109, USA.
Is Inbios International Inc. registered in SAM.gov?
Yes. Inbios International Inc.'s SAM.gov registration is active through December 10, 2026.
What is Inbios International Inc.'s most recent federal award?
Inbios International Inc.'s most recent federal contract award is Inbios reagents kits (75D30126P20991), from CDC Pittsburgh, on April 20, 2026.
On GovTribe
See Inbios International Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors